CBD is helping to establish cannabis as a legitimate products in the wellness market.
CBD, the more commonly known name for cannabidiol, is one of more than a hundred compounds found in the cannabis plant, and while there are several perceptions within the public around the benefits of CBD consumption, the most widely known fact about CBD is that it is non-psychoactive.
For most consumers, CBD products provide a healthy lifestyle
Overall, the increasing awareness about the medical applications of cannabidiol have caused several mainstream retailers to adapt and start selling CBD-based products, and many countries began to adopt CBD-based products for medicinal purposes.
The global cannabidiol market is expected to increase from $303m in 2018 to $2.28bn by 2025 while registering a CAGR of 33.5%, according to data compiled by QY Research.
Despite all the positive buzz around CBD products, obstacles remain and the regulatory infrastructure around such products remains complex. Currently, in America, most of the regulations surrounding hemp-derived CBD – especially as it relates to the consumer package goods (CPG) marketplace – are the domain of the FDA, which states that it is currently illegal to market CBD by adding it to a food or labelling it as a dietary supplement.
FDA Commissioner Scott Gottlieb, said: “This approval serves as a reminder that advancing sound development programs that properly evaluate active ingredients contained in marijuana can lead to important medical therapies. And, the FDA is committed to this kind of careful scientific research and drug development.”
This Blog has been edited
Source: Medical Cannabis Network